How effective is everolimus in breast cancer brain metastasis?

The efficacy of everolimus in breast cancer brain metastasis can be evaluated through the results of the LCCC 1025 clinical trial.

LCCC 1025 is a II phase study designed to evaluate the efficacy and safety of everolimus in combination with trastuzumab and vinorelbine in the treatment of HER2 patients with brain metastases from HER2-positive breast cancer. The trial is jointly participated by a number of well-known cancer research centers, including the University of North Carolina Lineberger Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center Orlando Hospital, etc.

The trial enrolled 32 patients with progressive HER2 brain metastases from breast cancer. The patient received combination therapy with everolimus + trastuzumab + vinorelbine.

Central nervous system clinical benefit rate, extracranial response rate, progression time, overall survival, and targeted tumor sequencing of enrolled patients.

Although the intracranial response rate is low, only 4% (partial response 1 case), the clinical benefit rate of the central nervous system is close to one-third, showing that this treatment regimen has a certain effect in controlling central nervous system symptoms. The median time to intracranial progression was 3.9 months and the median overall survival was 12.2 months, and these measures were similar to historical controls.

3～4 grade toxic reactions include neutropenia (41%), anemia (16%), stomatitis (16%), etc. These side effects require close monitoring and management.

LCCC 1025The results of the clinical trial show that everolimus combined with trastuzumab and vinorelbine in the treatment of HER2 patients with brain metastases from HER2-positive breast cancer has a certain effect in controlling central nervous system symptoms despite a low intracranial response rate. However, this treatment regimen is also associated with certain toxic effects that require close monitoring and management in clinical practice.

References:

https://ascopubs.org/doi/10.1200/jco.2012.30.15_suppl.tps656